Vascular calcifications in homozygote familial hypercholesterolemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 4, 2008, Pages 777-785

  Awan, Z ^a   Alrasadi, K ^a   Francis, G A ^b   Hegele, R A ^c   McPherson, R ^d   Frohlich, J ^e   Valenti, D ^a   De Varennes, B ^a   Marcil, M ^a   Gagne, C ^f   Genest, J ^a,g,h   Couture, P ^f  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITÉ LAVAL   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h MCGILL UNIVERSITY   (Canada)

Author keywords

Aorta; Calcification; Familial hypercholesterolemia

Indexed keywords

ADOLESCENT; ADULT; AORTA SURGERY; AORTA VALVE; ARTICLE; BLOOD VESSEL CALCIFICATION; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; AORTA DISEASE; BLOOD; CALCINOSIS; CANADA; CLINICAL TRIAL; ETHNIC GROUP; FOLLOW UP; GENETICS; HOMOZYGOTE; HYPERLIPOPROTEINEMIA TYPE 2; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; PRESCHOOL CHILD;

LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADOLESCENT; ADULT; AORTIC DISEASES; CALCINOSIS; CANADA; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, LDL; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUTATION; RECEPTORS, LDL;

EID: 42249103629     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.160408     Document Type: Article

References (46)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
2. Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, Naoumova R, Thompson GR, Seed M, Durrington PN, Miller JP, Betteridge DJ, Neil HA; Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet. 2006;43:943-949.
3. Tosi I, Toledo-Leiva P, Neuwirth C, Naoumova RP, Soutar AK. Genetic defects causing familial hypercholesterolaemia: Identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atherosclerosis. 2007;194:102-111.
4. Jensen JM, Gerdes LU, Jensen HK, Christiansen TM, Brorholt-Petersen JU, Faergeman O. Association of coronary heart disease with age-adjusted aortocoronary calcification in patients with familial hypercholesterolaemia. J Intern Med. 2000;247:479-484.
5. Moorjani S, Roy M, Gagne C, Davignon J, Brun D, Toussaint M, Lambert M, Campeau L, Blaichman S, Lupien P. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis. 1989;9:211-216.
6. Haitas B, Baker SG, Meyer TE, Joffe BI, Seftel HC. Natural history and cardiac manifestations of homozygous familial hypercholesterolaemia. Q J Med. 1990;76:731-740.
7. Kawaguchi A, Miyatake K, Yutani C, Beppu S, Tsushima M, Yamamura T, Yamamoto A. Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia. Am Heart J. 1999;137:410-418.
8. Kawaguchi A, Yutani C, Yamamoto A. Hypercholesterolemic valvulopathy: an aspect of malignant atherosclerosis. Ther Apher Dial. 2003;7:439-443.
9. Sprecher DL, Schaefer EJ, Kent KM, Gregg RE, Zech LA, Hoeg JM, McManus B, Roberts WC, Brewer HB Jr. Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. Am J Cardiol. 1984;54:20-30.
10. Brook GJ, Keidar S, Boulos M, Grenadier E, Wiener A, Shehada N, Markiewicz W, Benderli A, Aviram M. Familial homozygous hypercholesterolemia: clinical and cardiovascular features in 18 patients. Clin Cardiol. 1989;12:333-338.
11. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-1568.
12. Scriver CR. Human genetics: lessons from Quebec populations. Annu Rev Genomics Hum Genet. 2001;2:69-101.
13. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. BMJ (Clin Res Ed). 1985;291:1671-1673.
14. Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol. 2004;15:413-422. Review.
15. Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis. 2006;189:31-38.
16. West R, Gibson P, Lloyd J. Treatment of homozygous familial hypercholesterolaemia: an informative sibship. BMJ (Clin Res Ed). 1985;291:1079-1080.
17. Leren TP, Fagerhol MK, Leren P. Sixteen years of plasma exchange in a homozygote for familial hypercholesterolaemia. J Intern Med. 1993;233:195-200.
18. Grenon SM, Lachapelle K, Marcil M, Omeroglu A, Genest J, de Varennes B. Surgical strategies for severe. calcification of the aorta (porcelain aorta) in two patients with homozygous familial hypercholesterolemia. Can J Cardiol. 2007;23:1159-1161.
19. Saito S, Usui A, Akita T, Ueda Y. Surgery for calcific aortic root stenosis in homozygous familial hypercholesterolemia. Eur J Cardiothorac Surg. 2006;29:114-116.
20. Elghobary T, Allal J, Menu P, Baron O. Homograft replacement of the calcified aortic root in familial hypercholesterolemia. Ann Thorac Surg. 2006;81:e4-e5.
21. Yasuda T, Kawasuji M, Sakakibara N, Watanabe Y. Aortic valve replacement for the calcified ascending aorta in homozygous familial hypercholesterolemia. Eur J Cardiothorac Surg. 2000;18:249-250.
22. Bilal MS, Aydemir NA, Turan T. Ross-Konno procedure and ostial plasty in a child with homozygous hypercholesterolemia: case report. J Heart Valve Dis. 2005;14:855-858.
23. Hadfield SG, Humphries SE. Implementation of cascade testing for the detection of familial hypercholesterolaemia. Curr Opin Lipidol. 2005;16:428-433.
24. Vohl MC, Moorjani S, Roy M, Gaudet D, Torres AL, Minnich A, Gagne C, Tremblay G, Lambert M, Bergeron J, Couture P, Perron P, Blaichman S, Brun LD, Davignon J, Lupien PJ, Despres JP. Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the Province of Quebec. Clin Genet. 1997;52:1-6.
25. 1061(-1) G->-C] Atheroscler. 1999;146:125-131.
26. Wang J, Ban MR, Hegele RA. Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. J Lipid Res. 2005;46:366 -372.
27. Lehrman MA, Schneider WJ, Brown MS, Davis CG, Elhammer A, Russell DW, Goldstein JL. The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. J Biol Chem. 1987;262:401- 410.
28. Genest J Jr, Lavoie M-A. Homozygous familial hypercholesterolemia. Images in Clinical Medicine. New Eng J Med. 1999;341:490.
29. Raper SE, Grossman M, Rader DJ, Thoene JG, Clark BJ III, Kolansky DM, Muller DW, Wilson JM. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg. 1996;223:116-126.
30. Schmidt HH, Hill S, Makariou EV, Feuerstein IM, Dugi KA, Hoeg JM. Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia. Am J Cardiol. 1996;77:575-580.
31. Clarkson TB, Bond MG, Bullock BC, Marzetta CA. A study of atherosclerosis regression in maccaca mulatta. IV. Changes in coronary arteries from animals with atherosclerosis induced for 19 months and then regressed fro 24 or 48 months at plasma concentrations of 300 or 200 mg/dL. Exp Mol Pathol. 1981;34:345-368.
32. Houslay ES, Cowell SJ, Prescott RJ, Reid J, Burton J, Northridge DB, Boon NA, Newby DE; Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression trial Investigators. Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart. 2006;92:1207-1212.
33. Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb. 1994;14:1066-1074.
34. Stary HC. The development of calcium deposits in atherosclerotic lesions and their persistence after lipid regression. Am J Cardiol. 2001;88:16E-19E
35. Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart. 1998;80:583-590.
36. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004;24:1161-1170.
37. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15:2959-2964.
38. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89:1147-1154.
39. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res. 2006;99:1044-1059.
40. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002;105:2660-2665.
41. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003;107:2181-2184.
42. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47:1707-1712.
43. O'Brien KD. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol. 2006;26:1721-1728.
44. Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol. 2006;26:1423-1430.
45. Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation. 2006;114:2065-2069.
46. Vattikuti R, Towler DA. Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab. 2004;286:E686-E696.